Metformin vs Empagliflozin
Written by Aaron CuhaReviewed Sep 2026
The short answer
Both are pills and both are prescribed for type 2 diabetes. Only one has trials that report fewer deaths. Empagliflozin's ageing case rests on a single lab mouse study. Metformin's rests on decades of watching studies that proper trials have not confirmed.
- Metformin people
- 489
- Metformin nulls
- 0
- Empagliflozin people
- 16,738
- Empagliflozin nulls
- 1
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved for type 2 diabetes. It is also approved to cut the risk of dying from heart disease in adults with type 2 diabetes who already have heart disease, for heart failure whether the heart pumps weakly or normally, and for chronic kidney disease. Not approved for ageing, longevity or healthspan.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
MetforminMetformin hydrochloride (biguanide)
A cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training.
Column B
EmpagliflozinEmpagliflozin (sodium-glucose cotransporter 2 inhibitor)
A diabetes pill that also protects the heart and kidneys. Four big studies in more than 23,000 sick people found fewer deaths and fewer hospital stays. In the biggest diabetes study, 5.7 percent died on the drug and 8.3 percent on a dummy pill, 32 percent fewer deaths. Nobody has tested it for ageing in people. The whole ageing case is one mouse study from one lab, where male mice lived 5.9 percent longer.
Side by side, on the facts we can check
| What we compare | Metformin | Empagliflozin |
|---|---|---|
| Category | Longevity | Metabolic |
| FDA status | FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity. | FDA approved for type 2 diabetes. It is also approved to cut the risk of dying from heart disease in adults with type 2 diabetes who already have heart disease, for heart failure whether the heart pumps weakly or normally, and for chronic kidney disease. Not approved for ageing, longevity or healthspan. |
| Half-life | 4 to 9 hours (plasma), longer in erythrocytes | About 12 hours. |
| Molecular weight | 129.2 Da (165.6 Da as hydrochloride) | 450.9 Da |
| How it works | It blocks part of the energy machinery in mitochondria, called complex I, and switches on AMPK, a fuel sensor. That makes the liver release less sugar and helps the body respond to insulin. The AMPK story is not the whole answer. Research groups still argue over how much comes from complex I, from another enzyme called mitochondrial glycerophosphate dehydrogenase, and from effects in the gut. | It blocks a pump in the kidney called SGLT2. That pump normally pulls sugar back out of the urine. With it blocked, the sugar leaves the body. The heart and kidney benefit is bigger and faster than lower blood sugar alone explains. Nobody fully knows why. The leading ideas: less fluid in the blood, so the heart works less hard. Lower pressure inside the kidney's filters. The heart switching to a different fuel called ketones. And less salt build-up inside heart cells. The mouse work adds more ideas, like energy-sensing switches in cells and changes in gut bacteria. Those come from mice, which is a much weaker kind of evidence than the big human studies. |
| Studies in people | 7 | 4 |
| Evidence | Moderate: 3 completed trials, 489 people given it | Strong: 3 completed trials, 16,738 people given it |
| Legal status, US | Prescription only; approved for type 2 diabetes | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Metformin and Empagliflozin?
Metformin: A cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training. Empagliflozin: A diabetes pill that also protects the heart and kidneys. Four big studies in more than 23,000 sick people found fewer deaths and fewer hospital stays. In the biggest diabetes study, 5.7 percent died on the drug and 8.3 percent on a dummy pill, 32 percent fewer deaths. Nobody has tested it for ageing in people. The whole ageing case is one mouse study from one lab, where male mice lived 5.9 percent longer.
Which has stronger research evidence, Metformin or Empagliflozin?
Each compound gets a band worked out from facts we counted, with the math shown. Metformin is Moderate (3 completed trials, 489 people given it). Empagliflozin is Strong (3 completed trials, 16,738 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Metformin and Empagliflozin FDA-approved?
Metformin: FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.. Empagliflozin: FDA approved for type 2 diabetes. It is also approved to cut the risk of dying from heart disease in adults with type 2 diabetes who already have heart disease, for heart failure whether the heart pumps weakly or normally, and for chronic kidney disease. Not approved for ageing, longevity or healthspan..
Related posts
Blog articles that cover Metformin or Empagliflozin, newest first.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.